暴发性与非暴发性急性心肌炎的生存率及左心室功能变化
该回顾性研究纳入187例急性心肌炎患者,其中55例为暴发性(需正性肌力药和/或机械循环支持),132例为非暴发性。暴发性患者院内死亡或心脏移植率25.5% vs 非暴发性0%(P<0.0001),9年无移植生存率64.5% vs 100%(P<0.0001)。尽管暴发性患者住院期间LVEF改善更显著,但随访时LVEF<55%的比例更高(29% vs 9%)。
要点
- 暴发性心肌炎院内死亡或心脏移植风险显著高于非暴发性(25.5% vs 0%)。
- 暴发性心肌炎长期无移植生存率更低(9年64.5% vs 100%)。
- 暴发性心肌炎随访时LVEF<55%比例更高(29% vs 9%),尽管住院期间改善更明显。
核心结论
- 暴发性心肌炎患者死亡和心脏移植需求高于非暴发性心肌炎。
- 暴发性心肌炎患者入院时LVEF受损更严重,尽管住院期间改善显著,长期随访LVEF仍低于非暴发性患者。
- 上述结果在病毒性心肌炎亚组中同样成立,与既往显示暴发性心肌炎预后更好的研究不同。
研究设计与样本
- 暴发性心肌炎定义为需要正性肌力药和/或机械循环支持(55例),非暴发性为血流动力学稳定(132例)。
- 亚组分析纳入130例成人急性病毒性心肌炎(病毒前驱症状在 onset 2周内),其中暴发性34例,非暴发性96例。
- 排除巨细胞心肌炎、嗜酸性心肌炎、心脏结节病及年龄<15岁者(亚组分析中)。
主要发现
- 全人群(n=187)院内死亡或心脏移植率:暴发性25.5% vs 非暴发性0%(P<0.0001)。
- 9年无心脏移植生存率:暴发性64.5% vs 非暴发性100%(log-rank P<0.0001)。
- 住院期间LVEF改善中位数:暴发性32%(IQR 20%-40%) vs 非暴发性3%(IQR 0%-10%),P<0.0001。
- 末次随访LVEF<55%比例:暴发性29% vs 非暴发性9%(相对风险3.32,95%CI 1.45-7.64,P=0.003)。
- 亚组(n=130)病毒性心肌炎中生存率和LVEF变化结果与全人群相似。
关键数值与推荐
- 暴发性心肌炎定义:需要正性肌力药和/或机械循环支持。
- 非暴发性心肌炎定义:血流动力学稳定。
- 院内死亡或心脏移植率:暴发性25.5% vs 非暴发性0%(P<0.0001)。
- 9年无心脏移植生存率:暴发性64.5% vs 非暴发性100%(log-rank P<0.0001)。
- 末次随访LVEF<55%的相对风险:3.32(95%CI 1.45-7.64,P=0.003),暴发性 vs 非暴发性。
临床怎么用
- 暴发性心肌炎患者需警惕高院内死亡和心脏移植风险,应积极监护和支持治疗。
- 暴发性心肌炎患者出院后仍需长期随访左心室功能,因其LVEF可能持续低于正常。
- 非暴发性心肌炎患者若出院时LVEF≥55%,随访中未见显著LVEF下降。
局限性
- 回顾性研究设计。
- 亚组分析排除了巨细胞心肌炎、嗜酸性心肌炎、心脏结节病及年龄<15岁者。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous reports have suggested that despite their dramatic presentation, patients with fulminant myocarditis (FM) might have better outcome than those with acute nonfulminant myocarditis (NFM). In this retrospective study, we report outcome and changes in left ventricular ejection fraction (LVEF) in a large cohort of patients with FM compared with patients with NFM. METHODS: The study population consists of 187 consecutive patients admitted between May 2001 and November 2016 with a diagnosis of acute myocarditis (onset of symptoms <1 month) of whom 55 required inotropes and/or mechanical circulatory support (FM) and the remaining 132 were hemodynamically stable (NFM). We also performed a subanalysis in 130 adult patients with acute viral myocarditis and viral prodrome within 2 weeks from the onset, which includes 34 with FM and 96 with NFM. Patients with giant-cell myocarditis, eosinophilic myocarditis, or cardiac sarcoidosis and those <15 years of age were excluded from the subanalysis. RESULTS: In the whole population (n=187), the rate of in-hospital death or heart transplantation was 25.5% versus 0% in FM versus NFM, respectively (P<0.0001). Long-term heart transplantation-free survival at 9 years was lower in FM than NFM (64.5% versus 100%, log-rank P<0.0001). Despite greater improvement in LVEF during hospitalization in FM versus NFM forms (median, 32% [interquartile range, 20%-40%] versus 3% [0%-10%], respectively; P<0.0001), the proportion of patients with LVEF <55% at last follow-up was higher in FM versus NFM (29% versus 9%; relative risk, 3.32; 95% confidence interval, 1.45-7.64, P=0.003). Similar results for survival and changes in LVEF in FM versus NFM were observed in the subgroup (n=130) with viral myocarditis. None of the patients with NFM and LVEF ≥55% at discharge had a significant decrease in LVEF at follow-up. CONCLUSIONS: Patients with FM have an increased mortality and need for heart transplantation compared with those with NFM. From a functional viewpoint, patients with FM have a more severely impaired LVEF at admission that, despite steep improvement during hospitalization, remains lower than that in patients with NFM at long-term follow-up. These findings also hold true when only the viral forms are considered and are different from previous studies showing better prognosis in FM.
引用
- Ammirati E, Cipriani M, Lilliu M, et al. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation. 2017. PMID: 28576783. doi:10.1161/CIRCULATIONAHA.117.026386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。